Back to search

Article

Synuclein and dopamine transporter biomarkers among phenoconverters to parkinsonian disorders

2026-04-20

Abstract excerpt

<h4>Background</h4> Phenoconversion to Parkinson’s disease (PD) or dementia with Lewy bodies (DLB) currently relies on established clinical diagnostic criteria. Availability of in vivo biomarkers—CSF α-synuclein seed amplification assay (CSFaSynSAA) and dopamine transporter (DAT) imaging—offer the opportunity to investigate congruency between clinical phenoconversion and biologically defined disease. <h4>Method...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
63532257-5dd5-559a-a593-5789f3eadad7
DOI
10.64898/2026.04.15.26350768
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Synuclein and dopamine transporter biomarkers among phenoconverters to parkinsonian disordersDOI 10.64898/2026.04.15.26350768
Assessment of heterogeneity and disease onset in the Parkinson’s Progression Markers Initiative (PPMI) cohort using the α-synuclein seed amplification assay: a cross-sectional studySemantic proximity
Baseline α-synuclein seeding activity and disease progression in sporadic and genetic Parkinson’s disease in the PPMI cohortSemantic proximity
LRRK2-Associated Parkinsonism With and Without<i>In Vivo</i>Evidence of Alpha-Synuclein AggregatesSemantic proximity
Faster reaction times of CSF Alpha-Synuclein Seed Amplification Assay predict the Diffuse Malignant subtype of Parkinson’s Disease at 10-year follow-upSemantic proximity
Predicting Cerebrospinal Fluid Alpha-Synuclein Seed Amplification Assay Status from Demographics and Clinical DataSemantic proximity
Diagnostic and prognostic value of alpha-synuclein seed amplification assay in Parkinson’s disease: a longitudinal cohort studySemantic proximity
LRRK2 -associated parkinsonism with and without in vivo evidence of alpha-synuclein aggregates: longitudinal clinical and biomarker characterizationSemantic proximity
Digital risk score sensitively identifies presence of α-synuclein aggregation or dopaminergic deficitSemantic proximity
Quantitative Measurements of α-Synuclein Seeds in CSF Inform Diagnosis of SynucleinopathiesSemantic proximity
Clinical progression and genetic pathways in body-first and brain-first Parkinson's disease.Semantic proximity
FORECAST-RBD: Forecasting Phenoconversion Risks and Its Clinical Phenotype in Patients with Isolated RBD Using Machine Learning and Explainable AISemantic proximity
From phenotype to biology: a multi-modal roadmap of biofluid, tissue, imaging, and digital biomarkers in Parkinson's disease.Semantic proximity
Select a neighboring publication to make it the new centre.